Cargando…
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and immunogenicity of 2 clinical lots of V114 (investigational 15-valent pneumococcal vaccine: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F*, 23F,...
Autores principales: | Platt, Heather L., Greenberg, David, Tapiero, Bruce, Clifford, Robert A., Klein, Nicola P., Hurley, David C., Shekar, Tulin, Li, Jianing, Hurtado, Kim, Su, Shu-Chih, Nolan, Katrina M., Acosta, Camilo J., McFetridge, Richard D., Bickham, Kara, Musey, Luwy K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360095/ https://www.ncbi.nlm.nih.gov/pubmed/32639460 http://dx.doi.org/10.1097/INF.0000000000002765 |
Ejemplares similares
-
The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023) -
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022) -
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023) -
P06 The 15-valent pneumococcal conjugate vaccine (PCV) V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023) -
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
por: Mohapi, Lerato, et al.
Publicado: (2022)